Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 1, 2007, Pages 31-38

  Shim, Su Jung ^a   Yang, Woo Ick ^a   Shin, Eunah ^a   Koom, Woong Sub ^a   Kim, Yong Bae ^a   Cho, Jae Ho ^a   Suh, Chang Ok ^a   Kim, Joo Hang ^a   Kim, Gwi Eon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

COX 2; Natural Killer T cell lymphoma; Systemic recurrence

Indexed keywords

CELLS; CHEMOTHERAPY; HISTOLOGY; IMMUNOLOGY; PATIENT TREATMENT; RADIOTHERAPY;

PROGNOSIS; SURVIVAL DATA; SYSTEMIC RECURRENCE;

ENZYMES;

BLEOMYCIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOLINIC ACID; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NATURAL KILLER T CELL; NOSE CAVITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; T CELL LYMPHOMA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL;

ADOLESCENT; ADULT; AGED; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NOSE NEOPLASMS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33845777431     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.07.1387     Document Type: Article

References (35)

1. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
2. Halperin E.C., Dosoretz D.E., Goodman M., et al. Radiotherapy of polymorphic reticulosis. Br J Radiol 55 (1982) 645-649
3. Kassel S.H., Echevarria R.A., and Guzzo F.P. Midline malignant reticulosis (so-called lethal midline granuloma). Cancer 23 (1969) 920-935
4. Cheung M.M., Chan J.K., Lau W.H., et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: Clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16 (1998) 70-77
5. Ribrag V., Ell Hajj M., Janot F., et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 15 (2001) 1123-1126
6. Lei K.I., Suen J.J., Hui P., et al. Primary nasal and nasopharyngeal lymphomas: A comparative study of clinical presentation and treatment outcome. Clin Oncol (R Coll Radiol) 11 (1999) 379-387
7. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 69 (2000) 145-182
8. Williams C.S., Mann M., and DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18 (1999) 7908-7916
9. Elder D.J., Halton D.E., Hague A., et al. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression. Clin Cancer Res 3 (1997) 1679-1683
10. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (2000) 1306-1311
11. Hazar B., Ergin M., Seyrek E., et al. Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk Lymphoma 45 (2004) 1395-1399
12. Dannenberg A.J., and Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 4 (2003) 431-436
13. Pagano J.S. Viruses and lymphomas. N Engl J Med 347 (2002) 78-79
14. Chiang A.K., Chan A.C., Srivastava G., et al. Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage. Int J Cancer 73 (1997) 332-338
15. Tsuchiyama J., Yoshino T., Mori M., et al. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood 92 (1998) 1374-1383
16. Chan J.K., Yip T.T., Tsang W.Y., et al. Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol 18 (1994) 938-946
17. van Gorp J., Weiping L., Jacobse K., et al. Epstein-Barr virus in nasal T-cell lymphomas (polymorphic reticulosis/midline malignant reticulosis) in western China. J Pathol 173 (1994) 81-87
18. Jaffe E.S., Chan J.K., Su I.J., et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 20 (1996) 103-111
19. Subbaramaiah K., Telang N., Ramonetti J.T., et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 56 (1996) 4424-4429
20. Murono S., Inoue H., Tanabe T., et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 98 (2001) 6905-6910
21. Wun T., McKnight H., and Tuscano J.M. Increased cyclooxygenase-2 (COX-2): A potential role in the pathogenesis of lymphoma. Leuk Res 28 (2004) 179-190
22. Kim G.E., Cho J.H., Yang W.I., et al. Angiocentric lymphoma of the head and neck: Patterns of systemic failure after radiation treatment. J Clin Oncol 18 (2000) 54-63
23. Koom W.S., Chung E.J., Yang W.I., et al. Angiocentric T-cell and NK/T-cell lymphomas: Radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 59 (2004) 1127-1137
24. Chen W.C., McBride W.H., Chen S.M., et al. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: Clinical and in vitro studies. Head Neck 27 (2005) 503-512
25. Kim H.J., Wu H.G., Park I.A., et al. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 55 (2003) 16-20
26. Yamac D., Celenkoglu G., Coskun U., et al. Prognostic importance of COX-2 expression in patients with colorectal cancer. Pathol Res Pract 201 (2005) 497-502
27. Ranger G.S., Thomas V., Jewell A., et al. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res 24 (2004) 2349-2351
28. Byeon J.S., Jung H.Y., Lee Y.J., et al. Clinicopathological significance of vascular endothelial growth factor-C and cyclooxygenase-2 in esophageal squamous cell carcinoma. J Gastroenterol Hepatol 19 (2004) 648-654
29. Williams C.S., Tsujii M., Reese J., et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105 (2000) 1589-1594
30. Gallo O., Franchi A., Magnelli L., et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer: Implications for tumor angiogenesis and metastasis. Neoplasia 3 (2001) 53-61
31. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37 (2000) 431-502
32. Kawamori T., Rao C.V., Seibert K., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58 (1998) 409-412
33. Tsujii M., Kawano S., Tsuji S., et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
34. Milas L., Kishi K., Hunter N., et al. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91 (1999) 1501-1504
35. Pyo H., Choy H., Amorino G.P., et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7 (2001) 2998-3005